BioSpace News Archive

Drug Development

Relmada’s MDD Drug Misses Endpoint, Marred by “Paradoxical Results”

Relmada Therapeutics’ RELIANCE III trial studying REL-1017 as a treatment for Major Depressive Disorder failed to hit the primary endpoint, the company reported Thursday.

October 13, 2022
·
2 min read
·
Mark Terry
Drug Development

GSK Joins Pfizer in Driver’s Seat of RSV Vaccine Race

GSK’s RSV vaccine candidate met its primary endpoint in a pivotal Phase III trial, proving to be highly effective against RSV-associated lower respiratory tract disease.

October 13, 2022
·
3 min read
·
Tristan Manalac
Drug Development

Early Human Data Validates Effectiveness of Pfizer-BioNTech Omicron Booster

Pfizer and BioNTech released early data Thursday morning from a Phase II/III trial assessing an Omicron-specific booster that showed it provided significant protection, confirming early research.

October 13, 2022
·
2 min read
·
Alex Keown
Business

Odyssey Bags $168M to Accelerate Push to the Clinic

Odyssey Therapeutics raised $168 million in a Series B financing round, which will be used to advance its portfolio of immunomodulators and oncology therapies.

October 13, 2022
·
3 min read
·
Alex Keown
Business

$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart

One year after BridgeBio won accelerated approval for liver cancer drug Truseltiq (infigratinib), the company is pulling a planned Phase III program due to its partner’s decision to discontinue the drug.

October 13, 2022
·
2 min read
·
Alex Keown
Drug Development

Tiziana Plans IND for Intranasal Alzheimer’s Treatment with Promising CNS History

Tiziana Life Sciences plans to submit an Investigational New Drug Application for a Phase I trial studying intranasal formulab, a breakthrough treatment option for Alzheimer’s Disease.

October 13, 2022
·
3 min read
·
Kaley Lefevre
Business

Movers & Shakers: CEO Shakeups at BIO, Passage Bio and Palisade Bio

The Biotechnology Innovation Organization, Passage Bio and Palisade Bio saw leadership shakeups at the top, while Maze Therapeutics, Cerecin and more appointed new chief medical officers.

October 13, 2022
·
4 min read
·
Alex Keown
Business

ResMed to Report First Quarter Fiscal 2023 Earnings on October 27, 2022

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes.

October 13, 2022
·
1 min read
Business

Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2022 financial results will be released on Thursday, October 27 after the market closes.

October 13, 2022
·
1 min read
Genetown

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

Kymera Therapeutics, Inc. (NASDAQ: KYMR) will hold an investor webcast on December 14 to present clinical data from the KT-474 Phase 1 HS and AD patient cohort (Part C) and its oncology pipeline.

October 13, 2022
·
7 min read